GU Cancers 2024 | What does the future hold for radiopharmaceuticals in prostate cancer?

Geoffrey Johnson, MD, PhD, Mayo Clinic, Rochester, MN, discusses the emerging role of radiopharmaceuticals in the management of prostate cancer. Beta emitters have been particularly promising in the neoadjuvant setting and have been well received by patients due to low toxicity. Further studies will assess their efficacy in earlier stages and in combination with other therapies. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.